Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status

Shin, Bong Kyung; Lee, Youngseok; Lee, Jung Bok; Kim, Han Kyeom; Lee, Jae Bok; Cho, Su Jin; Kim, Aeree

doi:10.3892/or.19.3.617

Cited by 8 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We evaluated how hazard ratios for IHC subtypes were modified by race, menopausal status, and duration of follow-up, and also examined the contributions of tumor size, lymph node status and presence of metastatic disease. HRs for race, IHC subtypes, ER, PR, HER2 status and stage at diagnosis were consistent with previously reported data from other recent studies [3, 4, 6, 7, 10, 13, 15–26]. Patients with HER2+/ER− breast cancer had the worst prognosis, followed by basal-like.…”

Section: Discussionsupporting

confidence: 89%

“…Additionally, nearly all studies agree that basal-like and HER2+/ER- negative tumors have poorer prognoses than luminal A, regardless of the source population [3, 4, 6, 7, 10, 15–24]. However, many of these studies used only three IHC markers (ER, PR, and HER2) to classify subtypes, thus combining all basal-like and unclassified cancers into a single ‘triple negative’ subtype.…”

Section: Introductionmentioning

confidence: 99%

“…However, many of these studies used only three IHC markers (ER, PR, and HER2) to classify subtypes, thus combining all basal-like and unclassified cancers into a single ‘triple negative’ subtype. As several studies have corroborated that these two subtypes are biologically and prognostically distinct [4, 7, 13, 15, 22–23], subtype misclassification could substantially bias effect estimates.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study

O’Brien

Cole

Tse

et al. 2010

Clinical Cancer Research

382

296

View full text Add to dashboard Cite

Purpose: Previous research identified differences in breast cancer-specific mortality across 4 intrinsic tumor subtypes: luminal A, luminal B, basal-like, and human epidermal growth factor receptor 2 positive/ estrogen receptor negative (HER2Experimental Design: We used immunohistochemical markers to subtype 1,149 invasive breast cancer patients (518 African American, 631 white) in the Carolina Breast Cancer Study, a population-based study of women diagnosed with breast cancer. Vital status was determined through 2006 using the National Death Index, with median follow-up of 9 years.Results: Cancer subtypes luminal A, luminal B, basal-like, and HER2 þ /ER À were distributed as 64%, 11%, 11%, and 5% for whites, and 48%, 8%, 22%, and 7% for African Americans, respectively. Breast cancer mortality was higher for participants with HER2 þ /ER À and basal-like breast cancer compared with luminal A and B. African Americans had higher breast cancer-specific mortality than whites, but the effect of race was statistically significant only among women with luminal A breast cancer. However, when compared with the luminal A subtype within racial categories, mortality for participants with basal-like breast cancer was higher among whites (HR ¼ 2.0, 95% CI: 1.2-3.4) than African Americans (HR ¼ 1.5, 95% CI: 1.0-2.4), with the strongest effect seen in postmenopausal white women (HR ¼ 3.9, 95% CI: 1.5-10.0). Conclusions: Our results confirm the association of basal-like breast cancer with poor prognosis and suggest that basal-like breast cancer is not an inherently more aggressive disease in African American women compared with whites. Additional analyses are needed in populations with known treatment profiles to understand the role of tumor subtypes and race in breast cancer mortality, and in particular our finding that among women with luminal A breast cancer, African Americans have higher mortality than whites. Clin Cancer Res; 16(24); 6100-10. Ó2010 AACR.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study

O’Brien

Cole

Tse

et al. 2010

Clinical Cancer Research

382

296

View full text Add to dashboard Cite

show abstract

“…10,12 This result suggests that PPAR␥ itself possesses tumor promoting properties. 10,12 This result suggests that PPAR␥ itself possesses tumor promoting properties.…”

Section: Discussionmentioning

confidence: 86%

Correlated expression of peroxisome proliferator‐activated receptor γ with high histologic grade and basal type in invasive ductal carcinoma of the breast

Jeong¹,

Lee²,

An³

et al. 2009

Basic and Applied Pathology

Self Cite

View full text Add to dashboard Cite

Backgroud and aim:Peroxisome proliferator-activated receptor c (PPARc ) is one of the ligand-activated transcription factors belonging to the nuclear hormone receptor family. The protein is expressed in various kinds of tumor and has been implicated as a tumor suppressor in most cancers. We aimed to understand the role of PPARc in breast cancer. Methods: The expression of PPARc in 288 cases of invasive ductal carcinoma was examined using tissue microarray and immunohistochemistry. Results: PPARc immunoreactivity was detected in 21.5% of cases and significantly associated with expression of EGFR and ki-67 (P = 0.008; P = 0.046). PPARc expression was correlated with high histological grade and basal type (P ≤ 0.001; P = 0.009). Conclusions: PPARc expression is related to poor prognostic factors of breast cancer. It is considered that PPARc has evident tumor promoting properties in vivo, but receptor-independent effects of PPARc ligands may compound its biologic effects in cancer. A better understanding of action mechanisms of the activated PPARc is required.

show abstract

“…Noteworthy, as compared to the large body of information existing on p53 protein expression, little is known on p53 RNA levels in breast cancers (17). In addition, with regard to primary human DBC, p53-trancribed genes were generally analysed one at a time in separate studies, independently of p53 RNA expression (18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: A preliminary study

Albonici

Sorge²,

Santeusanio³

et al. 2010

Oncol Rep

View full text Add to dashboard Cite

Abstract. The protein expression of the growth suppressive p53 transcription factor and its inhibitor human double minute 2 (Hdm2) is altered in ductal breast carcinomas (DBC). However, the assessment of p53 and/or Hdm2 protein levels in DBC tissues was found to have a questionable prognostic significance. We evaluated the RNA expression of p53, hdm2, and the p53-targeted p21waf-1 and thrombospondin (tsp)-1 by primary DBC tissues, then correlated the RNA levels with patient clinicopathological data. The mean RNA expression level of p53 and that of hdm2 were elevated in large-sized, poorly differentiated, node-positive DBC, while a high p21waf-1 or tsp-1 mean expression level comprised small-sized, low-grade, node-negative tumors. Further analyses found that the correlation between the RNA expression of p53 and that of its targeted genes was reduced as tumor aggressiveness increased. However, for all the examined genes, association of the intensity of RNA expression with the pathological data was not statistically significant (p>0.05). Altogether, our preliminary RNA data confirm the results from previous protein studies, indicating that despite p53 expression and activity show a trend to vary in association with DBC clinical features, neither p53 nor its transcriptional targets can accurately monitor the behaviour of invasive DBC.

show abstract

Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status

Cited by 8 publications

References 34 publications

Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study

Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study

Correlated expression of peroxisome proliferator‐activated receptor γ with high histologic grade and basal type in invasive ductal carcinoma of the breast

Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: A preliminary study

Contact Info

Product

Resources

About